{"id":557767,"date":"2021-08-16T07:16:02","date_gmt":"2021-08-16T07:16:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=557767"},"modified":"2021-08-16T07:16:02","modified_gmt":"2021-08-16T07:16:02","slug":"the-phenylketonuria-treatment-market-is-expected-to-grow-significantly-due-to-the-launch-of-emerging-therapies-during-the-forecast-period-202130","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/the-phenylketonuria-treatment-market-is-expected-to-grow-significantly-due-to-the-launch-of-emerging-therapies-during-the-forecast-period-202130_557767.html","title":{"rendered":"The Phenylketonuria Treatment Market is Expected to Grow Significantly Due to the Launch of Emerging Therapies During the Forecast Period (2021-30)"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1629086548.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"The Phenylketonuria Treatment Market is Expected to Grow Significantly Due to the Launch of Emerging Therapies During the Forecast Period (2021-30)\" src=\"https:\/\/www.abnewswire.com\/uploads\/1629086548.png\" alt=\"The Phenylketonuria Treatment Market is Expected to Grow Significantly Due to the Launch of Emerging Therapies During the Forecast Period (2021-30)\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Phenylketonuria Market <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The launch of therapies such as SYNB1618 and others are anticipated to provide a major push to the growth of the Phenylketonuria market size in the forecast period 2021-30 in the 7MM.\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/2b669671e46c61c827d9fbf37b5866bb.jpg\" alt=\"\" \/><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight&#8217;s <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/phenylketonuria-pku-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Phenylketonuria market report<\/a><\/strong><span> provides <\/span><span>thorough comprehension<\/span><span> of Phenylketonuria, historical and forecasted epidemiology, and Phenylketonuria market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan).<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Key Highlights from the Phenylketonuria Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>According to DelveInsight&rsquo;s Phenylketonuria epidemiology insights, the total diagnosed prevalent cases was found to be <\/span><strong>49,887<\/strong><span> in the 7MM in 2020.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Among the EU5 countries, <\/span><span><strong>Germany<\/strong> <\/span><span>has the highest number of Phenylketonuria cases while <\/span><span><strong>Spain<\/strong> <\/span><span>has the least number of cases in 2020.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>According to the National PKU Alliance, there are currently more than <\/span><strong>16,000<\/strong><span> people in the United States who have PKU.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Key companies across the globe such as <\/span><strong>Synlogic, Censa Pharmaceuticals, Homology Medicines, Biomarin Pharmaceuticals, <\/strong><span>and others<\/span><span> are diligently working toward the development of novel treatment therapies and devices for Phenylketonuria treatment.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Synlogic&#8217;s SYNB-618<\/strong><span> was granted orphan drug designation by the US FDA in 2017 for the Phenylketonuria treatment, and it was also granted Fast track designation by the US FDA in 2018.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Homology Medicines<\/strong><span> is developing <\/span><strong>HMI-102<\/strong><span>, a gene therapy, for the treatment of adult patients with PKU.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Have queries? Request for the sample to get the answers for all your queries @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/phenylketonuria-pku-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Phenylketonuria Treatment Options<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Phenylketonuria (PKU) market report<\/strong><span> also covers current treatment practices, emerging drugs, Phenylketonuria (PKU) market share of individual therapies, and current and forecasted Phenylketonuria (PKU) market Size from 2018 to 2030, segmented by seven major markets.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Phenylketonuria: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Phenylketonuria (PKU) is an inborn metabolic error that can be detected during the first days of life through routine newborn screening. PKU is defined by the absence or deficiency of an enzyme called phenylalanine hydroxylase (PAH), which is responsible for the amino acid phenylalanine processing.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Phenylketonuria Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The Phenylketonuria report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Phenylketonuria Diagnosed Prevalent Cases&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Phenylketonuria Age-Specific Diagnosed Prevalent Cases&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Phenylketonuria Severity-Specific Diagnosed Prevalent Cases&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Phenylketonuria Diagnosed Prevalent Cases by Mutation Type<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Phenylketonuria Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>There is currently no cure for Phenylketonuria (PKU); however, the most common treatment is a dietary restriction of phenylalanine (Phe) to the minimum required for normal growth, supplemented with specially designed medical foods. As a result, <\/span><span>dietary therapy<\/span><span> is the first line of Phenylketonuria treatment. Apart from this, there are some FDA-approved drugs such as <\/span><span>Kuvan (sapropterin dihydrochloride) and Palynziq (pegvaliase-pqpz)<\/span><span> that are used for Phenylketonuria treatment.&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Phenylketonuria Market<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The launch of therapies such as <\/span><strong>SYNB1618, CNSA-001, HMI-102, <\/strong><span>and others by key pharmaceutical companies such as <\/span><strong>Synlogic, Censa Pharmaceuticals, Homology Medicines, <\/strong><span>and several others<\/span><span> are anticipated to provide a major push to the growth of the Phenylketonuria market size in the forecast period 2021-30 in the 7MM.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get a detailed analysis of the phenylketonuria therapeutics market @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/phenylketonuria-pku-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Phenylketonuria Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Phenylketonuria Pipeline Therapies and Key Companies<\/strong>&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>SYNB1618: <\/span><span>Synlogic<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>CNSA-001: <\/span><span>Censa Pharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>HMI-102: <\/span><span>Homology Medicines<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>BMN 307: Biomarin Pharmaceuticals<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><span>&nbsp;<\/span><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"58\" \/>\n<col width=\"566\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span>1.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Key insights<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>2.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Executive Summary of Phenylketonuria<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>3.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Phenylketonuria: Market Overview at a Glance<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>4.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disease Background and Overview: Phenylketonuria<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>5.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Phenylketonuria Patient Journey<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>6.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Case Reports<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>7.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Phenylketonuria<\/span><span>Epidemiology and Patient Population<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>8.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Phenylketonuria: Country-Wise Epidemiology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>9.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Phenylketonuria Treatment &amp; Medical Practices<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Phenylketonuria Marketed Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>11.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Phenylketonuria Emerging Therapies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>12.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Phenylketonuria Pipeline Profiles<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>13.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Phenylketonuria: Market Size<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>14.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>7MM Phenylketonuria: Country-Wise Market Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>15.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Phenylketonuria Market Drivers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>16.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Phenylketonuria Market Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>17.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>SWOT Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>18.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>KOL Views<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>19.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Phenylketonuria Reimbursement and market access<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>20.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>21.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DelveInsight Capabilities<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>22.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disclaimer<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>23.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>For rich insights into Healthcare and Pharmaceutical News, visit <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare, and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hyperphosphatemia-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Hyperphosphatemia Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get comprehensive historical and forecast analysis of <\/span><span>Hyperphosphatemia<\/span><span> Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as<\/span><strong> Akebia Therapeutics, Vifor Fresenius Medical Care Renal Pharma, Astellas Pharma, Ardelyx, Shield Therapeutics<\/strong><span><strong>,<\/strong>&nbsp;<\/span><span>among others.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=the-phenylketonuria-treatment-market-is-expected-to-grow-significantly-due-to-the-launch-of-emerging-therapies-during-the-forecast-period-202130\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=the-phenylketonuria-treatment-market-is-expected-to-grow-significantly-due-to-the-launch-of-emerging-therapies-during-the-forecast-period-202130\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Phenylketonuria Market The launch of therapies such as SYNB1618 and others are anticipated to provide a major push to the growth of the Phenylketonuria market size in the forecast period 2021-30 in the 7MM. DelveInsight&#8217;s Phenylketonuria market report provides thorough &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/the-phenylketonuria-treatment-market-is-expected-to-grow-significantly-due-to-the-launch-of-emerging-therapies-during-the-forecast-period-202130_557767.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,420,404],"tags":[],"class_list":["post-557767","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/557767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=557767"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/557767\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=557767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=557767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=557767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}